Novel uricase variants and their uses
Recombinant uricase variants with T cell epitope depletion mutations address the immunogenicity issues of existing therapies, improving efficacy and stability for treating gout and tumor lysis syndrome.
JP2026517792APending Publication Date: 2026-06-02INSMED INC
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- INSMED INC
- Filing Date
- 2024-05-03
- Publication Date
- 2026-06-02
Smart Images
Figure 2026517792000001_ABST
Abstract
This disclosure relates to chimeric pig-baboon uricase variants, Arthrobacter globiformis uricase variants, Aspergillus flavus uricase variants, and Candida utilis uricase variants, as well as methods for using them to treat gout, tumor lysis syndrome, and other diseases associated with elevated uric acid levels in body fluids, including blood. Methods for producing the uricase variants disclosed herein are also provided.
Need to check novelty before this filing date? Find Prior Art